NR 565 Advanced Pharmacology Final Exam Prep Document
| 2026/2027 Edition | 250 Verified Questions
NR 565 Advanced Pharmacology Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource contains 250 verified questions and answers for the NR
565 Advanced Pharmacology final exam, designed for advanced practice nursing students. The content
reflects the latest 2026/2027 academic year guidelines and covers essential pharmacology topics
including pharmacokinetics, pharmacodynamics, and therapeutic management across various patient
populations. Each question is accompanied by detailed rationales to reinforce clinical reasoning and
evidence-based prescribing practices. This document is an indispensable tool for achieving a top score
on the final exam.
Abstract:
The NR 565 Advanced Pharmacology Final Exam preparation document for the 2026/2027 academic year
provides advanced practice nursing students with 250 verified questions and answers that comprehensively cover
core pharmacology concepts. This resource emphasizes the clinical application of pharmacokinetic and
pharmacodynamic principles, focusing on safe and effective prescribing across diverse patient populations. Topics
include autonomic nervous system drugs, cardiovascular agents, endocrine therapies, respiratory medications,
neurological and psychiatric pharmacotherapy, antimicrobials, and pain management. Each question is paired
with a detailed rationale explaining the correct answer and common distractor errors, facilitating deep
understanding and retention. Updated to align with the latest guidelines from the American Nurses Association
and FDA, this document ensures students are prepared for the rigorous demands of advanced pharmacology
practice. The content is structured to mirror the exam blueprint, with weighted sections that reflect the emphasis on
high-stakes clinical decision-making. Mastery of these questions will enable students to achieve a grade of A+ and
excel in their clinical roles.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
Autonomic Nervous System 41-70 Cholinergic, anticholinergic, adrenergic, 12%
Pharmacology antiadrenergic agents
Cardiovascular Pharmacology 71-100 Antihypertensives, antiarrhythmics, heart 12%
failure drugs, anticoagulants
Endocrine Pharmacology 101-130 Diabetes medications, thyroid drugs, 12%
corticosteroids, sex hormones
Respiratory and Gastrointestinal 131-160 Asthma/COPD drugs, antihistamines, proton 12%
Pharmacology pump inhibitors, antiemetics
Neurological and Psychiatric 161-190 Antidepressants, antipsychotics, 12%
Pharmacology anticonvulsants, Parkinson's drugs,
analgesics
Antimicrobial Therapy 191-220 Antibiotics, antivirals, antifungals, 12%
resistance mechanisms, immunizations
Special Populations and Pain 221-250 Pediatric, geriatric, pregnancy, opioid 12%
Management prescribing, non-opioid analgesics
Page 1
,Q1. A patient on warfarin develops a subtherapeutic INR after starting a course of
rifampin. Which mechanism best explains this interaction?
A. Rifampin displaces warfarin from albumin, increasing free warfarin and its
clearance.
B. Rifampin induces CYP2C9 and CYP3A4, accelerating warfarin metabolism.
C. Rifampin inhibits vitamin K epoxide reductase, counteracting warfarin effect.
D. Rifampin reduces gastrointestinal absorption of warfarin by altering gut flora.
Correct Answer: B. Rifampin induces CYP2C9 and CYP3A4, accelerating warfarin
metabolism.
Rationale: Rifampin is a potent inducer of CYP2C9 and CYP3A4, the enzymes that
metabolize S-warfarin and R-warfarin, respectively. Induction increases warfarin
clearance, leading to subtherapeutic INR. Displacement from albumin (A) is transient and
not the primary mechanism. Inhibition of VKOR (C) would increase warfarin effect.
Altered gut flora (D) is not a major mechanism for warfarin-rifampin interaction.
Why Wrong:
A - Displacement from albumin causes a transient increase in free drug but is rapidly
offset by increased clearance; it does not explain sustained subtherapeutic INR.
C - Rifampin does not inhibit VKOR; it induces warfarin metabolism, opposite effect.
D - Rifampin does not significantly affect warfarin absorption; the interaction is
metabolic.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34, 43.
Q2. In a patient with diabetic nephropathy (eGFR 35 mL/min) and persistent
proteinuria, which antihypertensive agent is most likely to delay progression of
kidney disease?
A. Amlodipine
B. Losartan
C. Hydrochlorothiazide
D. Metoprolol
Correct Answer: B. Losartan
Rationale: Losartan, an angiotensin II receptor blocker (ARB), reduces intraglomerular
pressure and proteinuria, slowing progression of diabetic nephropathy. This benefit is
independent of blood pressure reduction. Amlodipine (A) and metoprolol (D) do not have
proven renoprotective effects. Hydrochlorothiazide (C) is less effective in advanced CKD
(eGFR <30) and does not specifically reduce proteinuria.
Why Wrong:
A - Amlodipine is effective for BP but lacks the renoprotective, antiproteinuric effects
of ARBs/ACEIs.
C - Thiazides are ineffective when eGFR <30 and do not reduce proteinuria.
Page 2
, D - Beta-blockers are not first-line for renoprotection in diabetic nephropathy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29, 48.
Q3. A patient with major depressive disorder has not responded to adequate trials of
two different SSRIs and one SNRI. Which pharmacologic strategy is best supported
by evidence for treatment-resistant depression?
A. Add a low-dose atypical antipsychotic such as aripiprazole.
B. Switch to a monoamine oxidase inhibitor (MAOI) as monotherapy.
C. Augment with buspirone 30 mg daily.
D. Discontinue all antidepressants and start electroconvulsive therapy (ECT).
Correct Answer: A. Add a low-dose atypical antipsychotic such as aripiprazole.
Rationale: Augmentation with an atypical antipsychotic (e.g., aripiprazole, quetiapine) is
an evidence-based strategy for treatment-resistant depression. MAOIs (B) are effective but
require dietary restrictions and are not first-line after only two failed trials. Buspirone
augmentation (C) has modest evidence. ECT (D) is reserved for severe cases after multiple
medication failures.
Why Wrong:
B - MAOIs are effective but carry significant risk and are not typically used after only
two failed classes.
C - Buspirone augmentation has weak evidence compared to atypical antipsychotics.
D - ECT is a later-line option after pharmacological augmentation has failed.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 17.
Q4. Which statement best describes the effect of a drug that acts as a partial agonist
at the mu-opioid receptor?
A. It produces maximal analgesic effect similar to morphine at high doses.
B. It has a ceiling effect for analgesia and a lower risk of respiratory depression.
C. It competitively antagonizes full agonists at the receptor.
D. It produces no analgesic effect but prevents withdrawal symptoms.
Correct Answer: B. It has a ceiling effect for analgesia and a lower risk of respiratory
depression.
Rationale: Partial agonists have lower intrinsic efficacy than full agonists, producing a
ceiling effect for both analgesia and respiratory depression, which improves safety. They
do not achieve maximal effect (A). They are not antagonists (C) and do produce analgesia
(D).
Why Wrong:
A - Partial agonists cannot produce maximal effect; they have a ceiling.
C - Partial agonists activate the receptor, they do not antagonize.
D - Partial agonists produce analgesia, though less than full agonists.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13.
Q5. A patient with asthma uses a high-dose inhaled corticosteroid (ICS) and a
long-acting beta-agonist (LABA). Despite adherence, symptoms persist. Which
add-on therapy is recommended by current GINA guidelines?
A. Add oral theophylline.
B. Add a leukotriene receptor antagonist (LTRA).
C. Add tiotropium (long-acting muscarinic antagonist).
D. Increase LABA dose.
Correct Answer: C. Add tiotropium (long-acting muscarinic antagonist).
Rationale: GINA 2026 recommends adding tiotropium as add-on therapy for patients with
uncontrolled asthma despite ICS/LABA. LTRAs (B) are an option but less preferred.
Theophylline (A) is third-line due to narrow therapeutic index. Increasing LABA dose (D)
is not recommended due to safety concerns.
Why Wrong:
A - Theophylline is less effective and has significant toxicity; not first add-on.
B - LTRA is an option but tiotropium is preferred per GINA step 5.
D - Higher LABA doses increase risk of adverse effects without proportional benefit.
Reference: Global Initiative for Asthma (GINA). (2026). Pocket Guide for Asthma
Management.
Q6. A patient on digoxin develops nausea, vomiting, and visual disturbances. ECG
shows new-onset atrial fibrillation with slow ventricular response. Which intervention
is most appropriate?
A. Administer digoxin immune Fab fragments.
B. Administer intravenous calcium gluconate.
C. Increase digoxin dose to control arrhythmia.
D. Start amiodarone for rhythm control.
Correct Answer: A. Administer digoxin immune Fab fragments.
Rationale: Symptoms and ECG findings suggest digoxin toxicity. Digoxin immune Fab
fragments bind digoxin, reversing toxicity. Calcium (B) is used for hyperkalemia in
digoxin toxicity but not for arrhythmia. Increasing digoxin (C) would worsen toxicity.
Amiodarone (D) can increase digoxin levels and is not first-line.
Why Wrong:
B - Calcium is for hyperkalemia; it does not reverse digoxin toxicity.
C - Increasing dose would exacerbate toxicity.
D - Amiodarone may increase digoxin levels and is not indicated for acute toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 24.
Page 4
| 2026/2027 Edition | 250 Verified Questions
NR 565 Advanced Pharmacology Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource contains 250 verified questions and answers for the NR
565 Advanced Pharmacology final exam, designed for advanced practice nursing students. The content
reflects the latest 2026/2027 academic year guidelines and covers essential pharmacology topics
including pharmacokinetics, pharmacodynamics, and therapeutic management across various patient
populations. Each question is accompanied by detailed rationales to reinforce clinical reasoning and
evidence-based prescribing practices. This document is an indispensable tool for achieving a top score
on the final exam.
Abstract:
The NR 565 Advanced Pharmacology Final Exam preparation document for the 2026/2027 academic year
provides advanced practice nursing students with 250 verified questions and answers that comprehensively cover
core pharmacology concepts. This resource emphasizes the clinical application of pharmacokinetic and
pharmacodynamic principles, focusing on safe and effective prescribing across diverse patient populations. Topics
include autonomic nervous system drugs, cardiovascular agents, endocrine therapies, respiratory medications,
neurological and psychiatric pharmacotherapy, antimicrobials, and pain management. Each question is paired
with a detailed rationale explaining the correct answer and common distractor errors, facilitating deep
understanding and retention. Updated to align with the latest guidelines from the American Nurses Association
and FDA, this document ensures students are prepared for the rigorous demands of advanced pharmacology
practice. The content is structured to mirror the exam blueprint, with weighted sections that reflect the emphasis on
high-stakes clinical decision-making. Mastery of these questions will enable students to achieve a grade of A+ and
excel in their clinical roles.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
Autonomic Nervous System 41-70 Cholinergic, anticholinergic, adrenergic, 12%
Pharmacology antiadrenergic agents
Cardiovascular Pharmacology 71-100 Antihypertensives, antiarrhythmics, heart 12%
failure drugs, anticoagulants
Endocrine Pharmacology 101-130 Diabetes medications, thyroid drugs, 12%
corticosteroids, sex hormones
Respiratory and Gastrointestinal 131-160 Asthma/COPD drugs, antihistamines, proton 12%
Pharmacology pump inhibitors, antiemetics
Neurological and Psychiatric 161-190 Antidepressants, antipsychotics, 12%
Pharmacology anticonvulsants, Parkinson's drugs,
analgesics
Antimicrobial Therapy 191-220 Antibiotics, antivirals, antifungals, 12%
resistance mechanisms, immunizations
Special Populations and Pain 221-250 Pediatric, geriatric, pregnancy, opioid 12%
Management prescribing, non-opioid analgesics
Page 1
,Q1. A patient on warfarin develops a subtherapeutic INR after starting a course of
rifampin. Which mechanism best explains this interaction?
A. Rifampin displaces warfarin from albumin, increasing free warfarin and its
clearance.
B. Rifampin induces CYP2C9 and CYP3A4, accelerating warfarin metabolism.
C. Rifampin inhibits vitamin K epoxide reductase, counteracting warfarin effect.
D. Rifampin reduces gastrointestinal absorption of warfarin by altering gut flora.
Correct Answer: B. Rifampin induces CYP2C9 and CYP3A4, accelerating warfarin
metabolism.
Rationale: Rifampin is a potent inducer of CYP2C9 and CYP3A4, the enzymes that
metabolize S-warfarin and R-warfarin, respectively. Induction increases warfarin
clearance, leading to subtherapeutic INR. Displacement from albumin (A) is transient and
not the primary mechanism. Inhibition of VKOR (C) would increase warfarin effect.
Altered gut flora (D) is not a major mechanism for warfarin-rifampin interaction.
Why Wrong:
A - Displacement from albumin causes a transient increase in free drug but is rapidly
offset by increased clearance; it does not explain sustained subtherapeutic INR.
C - Rifampin does not inhibit VKOR; it induces warfarin metabolism, opposite effect.
D - Rifampin does not significantly affect warfarin absorption; the interaction is
metabolic.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34, 43.
Q2. In a patient with diabetic nephropathy (eGFR 35 mL/min) and persistent
proteinuria, which antihypertensive agent is most likely to delay progression of
kidney disease?
A. Amlodipine
B. Losartan
C. Hydrochlorothiazide
D. Metoprolol
Correct Answer: B. Losartan
Rationale: Losartan, an angiotensin II receptor blocker (ARB), reduces intraglomerular
pressure and proteinuria, slowing progression of diabetic nephropathy. This benefit is
independent of blood pressure reduction. Amlodipine (A) and metoprolol (D) do not have
proven renoprotective effects. Hydrochlorothiazide (C) is less effective in advanced CKD
(eGFR <30) and does not specifically reduce proteinuria.
Why Wrong:
A - Amlodipine is effective for BP but lacks the renoprotective, antiproteinuric effects
of ARBs/ACEIs.
C - Thiazides are ineffective when eGFR <30 and do not reduce proteinuria.
Page 2
, D - Beta-blockers are not first-line for renoprotection in diabetic nephropathy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29, 48.
Q3. A patient with major depressive disorder has not responded to adequate trials of
two different SSRIs and one SNRI. Which pharmacologic strategy is best supported
by evidence for treatment-resistant depression?
A. Add a low-dose atypical antipsychotic such as aripiprazole.
B. Switch to a monoamine oxidase inhibitor (MAOI) as monotherapy.
C. Augment with buspirone 30 mg daily.
D. Discontinue all antidepressants and start electroconvulsive therapy (ECT).
Correct Answer: A. Add a low-dose atypical antipsychotic such as aripiprazole.
Rationale: Augmentation with an atypical antipsychotic (e.g., aripiprazole, quetiapine) is
an evidence-based strategy for treatment-resistant depression. MAOIs (B) are effective but
require dietary restrictions and are not first-line after only two failed trials. Buspirone
augmentation (C) has modest evidence. ECT (D) is reserved for severe cases after multiple
medication failures.
Why Wrong:
B - MAOIs are effective but carry significant risk and are not typically used after only
two failed classes.
C - Buspirone augmentation has weak evidence compared to atypical antipsychotics.
D - ECT is a later-line option after pharmacological augmentation has failed.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 17.
Q4. Which statement best describes the effect of a drug that acts as a partial agonist
at the mu-opioid receptor?
A. It produces maximal analgesic effect similar to morphine at high doses.
B. It has a ceiling effect for analgesia and a lower risk of respiratory depression.
C. It competitively antagonizes full agonists at the receptor.
D. It produces no analgesic effect but prevents withdrawal symptoms.
Correct Answer: B. It has a ceiling effect for analgesia and a lower risk of respiratory
depression.
Rationale: Partial agonists have lower intrinsic efficacy than full agonists, producing a
ceiling effect for both analgesia and respiratory depression, which improves safety. They
do not achieve maximal effect (A). They are not antagonists (C) and do produce analgesia
(D).
Why Wrong:
A - Partial agonists cannot produce maximal effect; they have a ceiling.
C - Partial agonists activate the receptor, they do not antagonize.
D - Partial agonists produce analgesia, though less than full agonists.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13.
Q5. A patient with asthma uses a high-dose inhaled corticosteroid (ICS) and a
long-acting beta-agonist (LABA). Despite adherence, symptoms persist. Which
add-on therapy is recommended by current GINA guidelines?
A. Add oral theophylline.
B. Add a leukotriene receptor antagonist (LTRA).
C. Add tiotropium (long-acting muscarinic antagonist).
D. Increase LABA dose.
Correct Answer: C. Add tiotropium (long-acting muscarinic antagonist).
Rationale: GINA 2026 recommends adding tiotropium as add-on therapy for patients with
uncontrolled asthma despite ICS/LABA. LTRAs (B) are an option but less preferred.
Theophylline (A) is third-line due to narrow therapeutic index. Increasing LABA dose (D)
is not recommended due to safety concerns.
Why Wrong:
A - Theophylline is less effective and has significant toxicity; not first add-on.
B - LTRA is an option but tiotropium is preferred per GINA step 5.
D - Higher LABA doses increase risk of adverse effects without proportional benefit.
Reference: Global Initiative for Asthma (GINA). (2026). Pocket Guide for Asthma
Management.
Q6. A patient on digoxin develops nausea, vomiting, and visual disturbances. ECG
shows new-onset atrial fibrillation with slow ventricular response. Which intervention
is most appropriate?
A. Administer digoxin immune Fab fragments.
B. Administer intravenous calcium gluconate.
C. Increase digoxin dose to control arrhythmia.
D. Start amiodarone for rhythm control.
Correct Answer: A. Administer digoxin immune Fab fragments.
Rationale: Symptoms and ECG findings suggest digoxin toxicity. Digoxin immune Fab
fragments bind digoxin, reversing toxicity. Calcium (B) is used for hyperkalemia in
digoxin toxicity but not for arrhythmia. Increasing digoxin (C) would worsen toxicity.
Amiodarone (D) can increase digoxin levels and is not first-line.
Why Wrong:
B - Calcium is for hyperkalemia; it does not reverse digoxin toxicity.
C - Increasing dose would exacerbate toxicity.
D - Amiodarone may increase digoxin levels and is not indicated for acute toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 24.
Page 4
